GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals, the British drugmaker said on Wednesday. Efimosfermin, a monthly subcutaneous injection,

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their exclusivity periods.

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, have announced that they